RAPT Therapeutics, Inc. - Common Stock (NQ:RAPT)

58.02 UNCHANGED

Last Price Updated: 4:00 PM EST, Mar 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about RAPT Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

This Biotech Was Quietly Bought Before a $58 Per Share Takeout ↗

March 21, 2026

This clinical-stage biotech develops oral therapies targeting cancer and inflammatory diseases, with lead candidates in active trials.

Via The Motley Fool

This Investor Built a $56 Million Position in RAPT Last Quarter. It Was Just Acquired for $58 Per Share ↗

March 15, 2026

RAPT Therapeutics develops oral therapies for cancer and inflammation, with key drug candidates currently in clinical trials.

Via The Motley Fool

Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million ↗

February 25, 2026

This biotech specializes in monoclonal antibody therapies for inflammatory and immunological diseases with significant unmet needs.

Via The Motley Fool

Topics Regulatory Compliance

RAPT THERAPEUTICS INC (NASDAQ:RAPT) Shows High Technical and Pattern Scores Ahead of Potential Breakout ↗

February 18, 2026

Via Chartmill

This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges ↗

February 25, 2026

RAPT Therapeutics develops oral therapies for oncology and inflammatory diseases, with lead candidates progressing in clinical trials.

Via The Motley Fool

Topics Regulatory Compliance

Disc Medicine Lands New $20 Million Investment as FDA Sets Up Potential Q4 Catalyst ↗

February 25, 2026

This clinical-stage biotech develops therapies targeting hematologic disorders, with a pipeline centered on red blood cell biology.

Via The Motley Fool

Topics Regulatory Compliance

Halper Sadeh LLC is Investigating Whether RAPT, CTGO, TBN, FOLD are Obtaining Fair Deals for their Shareholders

February 19, 2026

From Halper Sadeh LLC

Via GlobeNewswire

RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT

February 05, 2026

From Kahn Swick & Foti, LLC

Via Business Wire

Halper Sadeh LLC Reminds Shareholders of RAPT, PEN, CVGW, FONR of the Firm’s Investigations

February 02, 2026

Shareholders should contact the firm as there may be limited time to enforce your rights.

From Halper Sadeh LLC

Via GlobeNewswire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RAPT Therapeutics, Inc. (Nasdaq – RAPT), Penumbra, Inc. (NYSE – PEN), Calavo Growers, Inc. (Nasdaq – CVGW), FONAR Corporation (Nasdaq - FONR)

February 02, 2026

From Brodsky & Smith LLC

Via GlobeNewswire

Halper Sadeh LLC Reminds Shareholders of JHG, FOLD, RAPT of the Firm’s Investigations

February 02, 2026

Shareholders should contact the firm as there may be limited time to enforce your rights

From Halper Sadeh LLC

Via GlobeNewswire

Halper Sadeh LLC Encourages NATH, PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights

January 29, 2026

Shareholders should contact the firm as there may be limited time to enforce your rights

From Halper Sadeh LLC

Via GlobeNewswire

Halper Sadeh LLC Encourages PEN and RAPT Shareholders to Contact the Firm to Discuss Their Rights

January 27, 2026

Shareholders should contact the firm as there may be limited time to enforce your rights

From Halper Sadeh LLC

Via GlobeNewswire

The Great Consolidation: US M&A Values Double as AI and Bio-Pharma Spark $2 Trillion Surge

January 26, 2026

As of January 26, 2026, the American corporate landscape is undergoing its most radical transformation in a generation. Following a two-year period of high-interest-rate hibernation, the United States...

Via MarketMinute

Topics Artificial Intelligence Economy

Halper Sadeh LLC Encourages NATH, RAPT, FONR Shareholders to Contact the Firm to Discuss Their Rights

January 23, 2026

Shareholders should contact the firm as there may be limited time to enforce your rights

From Halper Sadeh LLC

Via GlobeNewswire

RAPT Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RAPT Therapeutics, Inc. - RAPT

January 21, 2026

From Kahn Swick & Foti, LLC

Via Business Wire

Why Rapt Therapeutics Stock Soared Today ↗

January 20, 2026

A global healthcare giant wants to acquire the biotech's promising development program.

Via The Motley Fool

January 20, 2026

From Brodsky & Smith LLC

Via GlobeNewswire

Here are the top movers in Tuesday's session. ↗

January 20, 2026

Via Chartmill

Tuesday's session: top gainers and losers ↗

January 20, 2026

Via Chartmill

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

January 20, 2026

Via Chartmill

GSK Challenges Xolair Dominance with $2.2 Billion Acquisition of RAPT Therapeutics

January 20, 2026

In a bold strategic opening to the 2026 fiscal year, pharmaceutical giant GSK (NYSE:GSK) has announced a definitive agreement to acquire RAPT Therapeutics (Nasdaq:RAPT) for approximately $2.2 billion....

Via MarketMinute

Topics Intellectual Property

Wondering what's happening in today's pre-market session? ↗

January 20, 2026

Via Chartmill

RAPT Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of RAPT Therapeutics, Inc. is Fair to Shareholders

January 20, 2026

From Halper Sadeh LLC

Via Business Wire

Why Did RAPT Stock Surge 63% In Pre-Market Today? ↗

January 20, 2026

GSK will acquire RAPT for $58.00 per share in cash, a 65.2% premium over Friday’s closing price of $35.1.

Via Stocktwits

RAPT Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 07, 2026

From RAPT Therapeutics, Inc.

Via GlobeNewswire

This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits ↗

December 29, 2025

A full exit during a volatile stretch raises a sharper question than timing alone.

Via The Motley Fool

Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally

November 07, 2025

The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

November 06, 2025

From RAPT Therapeutics, Inc.

Via GlobeNewswire

RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences

November 04, 2025

From RAPT Therapeutics, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.